Literature DB >> 19261977

Cytochrome P-450 metabolites in renal circulation and excretion--interaction with the nitric oxide (NO) system.

E Kompanowska-Jezierska1, M Kuczeriszka.   

Abstract

The role of CYP-450 dependent arachidonic acid (AA) metabolites (vasoconstrictor 20-HETE and vasodilator EETs) and NO in control of blood pressure (MABP) and kidney function remains unclear. NO affects the activity of heme-containing enzymes, like CYP-450 related monooxygenases, moreover, their activity depends on Na(+) intake. The focus of this review and underlying studies is on the role of high sodium intake (pro-hypertensive factor) in interrelation between CYP-450 and NOS. The acute vs. chronic non-selective inhibition of CYP-450 AA metabolites (ABT), and selective inhibition of 20-HETE (HET 0016) has also been tested. The renal artery flow (RBF, Transonic probe), medullary blood flow (MBF, laser-Doppler flux), renal excretion, and medullary tissue NO (selective electrode) were measured in male anaesthetized Wistar rats. We conclude that on standard Na(+) intake, opposed effects of 20-HETE and EETs are almost in equilibrium; however, in the renal circulation the vasodilator EETs influence slightly prevails. High sodium intake stimulates NOS, which limits CYP-450 impact on MABP and kidney function. However, this protection disappears after prolonged sodium intake. Long-lasting high sodium intake lowers NO bioavailability and promotes systemic and intrarenal vasoconstrictor activity of 20-HETE. Opposed effects of NO and AA metabolites of CYP-450 on water and solute excretion are also described.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19261977

Source DB:  PubMed          Journal:  J Physiol Pharmacol        ISSN: 0867-5910            Impact factor:   3.011


  1 in total

1.  Different mechanisms of acute versus long-term antihypertensive effects of soluble epoxide hydrolase inhibition: studies in Cyp1a1-Ren-2 transgenic rats.

Authors:  Alexandra Sporková; Sárka Jíchová; Zuzana Husková; Libor Kopkan; Akira Nishiyama; Sung H Hwang; Bruce D Hammock; John D Imig; Elzbieta Kompanowska-Jezierska; Janusz Sadowski; Herbert J Kramer; Luděk Cervenka
Journal:  Clin Exp Pharmacol Physiol       Date:  2014-12       Impact factor: 2.557

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.